Skip to main content
JANGHO GROUP CO., LTD. logo

JANGHO GROUP CO., LTD. — Investor Relations & Filings

Ticker · 601886 ISIN · CNE100001682 LEI · 300300I8B6L242A4UJ04 Shanghai Stock Exchange Construction
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2018-11-28 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 601886

About JANGHO GROUP CO., LTD.

https://www.jangho.com/

Jangho Group Co., Ltd. specializes in the design, fabrication, and installation of high-end building envelope systems and architectural decoration services. The company operates through two primary business segments: architectural decoration and healthcare. Its architectural decoration division focuses on curtain wall systems, including glass, aluminum, and stone facades for large-scale commercial and public infrastructure projects. Through its subsidiaries, the group also provides comprehensive interior fit-out and design services. In the healthcare sector, the company has expanded into ophthalmology and medical services. Jangho Group is recognized for its technical expertise in complex structural engineering and its involvement in the construction of numerous landmark skyscrapers and urban complexes globally. The company emphasizes integrated solutions that combine aesthetic design with functional performance and energy efficiency.

Recent filings

Filing Released Lang Actions
关于首次实施回购股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first implementation of a share repurchase program, detailing the number of shares bought back, prices, and total amount spent. It references relevant regulations and previous shareholder meeting approvals. The content focuses on the company's own shares transaction activity rather than financial results or other report types. Therefore, it fits the category of a Transaction in Own Shares (POS) filing.
2018-11-28 Chinese
关于收到上海证券交易所对公司股权收购事项问询函的回复公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jianghe Group regarding their response to an inquiry letter from the Shanghai Stock Exchange about a share acquisition matter. It discusses details about shareholding changes, investment rationale, and strategic considerations related to the company's medical business segment. The document is relatively short (2119 characters) and primarily serves as a regulatory disclosure responding to a regulatory inquiry rather than a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-11-27 Chinese
关于重大工程中标的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about a significant engineering contract award by the company. It includes details about the contract value, project location, and duration. It does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, nor a regulatory filing about governance or legal matters. It is an announcement related to a business development (winning a major contract). This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-11-26 Chinese
关于收到上海证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jianghe Group regarding the receipt of an inquiry letter from the Shanghai Stock Exchange about a related party transaction involving the acquisition of equity by a wholly-owned subsidiary. It details the background of the transaction, the inquiry questions, and the company's commitment to respond. The document is short (1152 characters) and does not contain financial statements or detailed financial data. It is an official regulatory communication about a disclosure inquiry rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2018-11-26 Chinese
北京江河康健医疗管理有限公司拟收购北京江河源控股有限公司持有的首颐医疗健康投资管理有限公司股权涉及的股东全部权益价值项目估值报告
Capital/Financing Update Classification · 95% confidence The document is a detailed valuation report for the acquisition of equity in a company, including valuation methods, financial data, assumptions, and conclusions. It is titled as an "估值报告" (valuation report) and contains extensive financial analysis, valuation methodologies (market approach, income approach), and a final valuation conclusion. It is not an announcement or a brief summary but a full report with substantive financial and valuation content. It does not fit into categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER) because it is specifically a valuation report related to a transaction. The closest fitting category from the provided list is "Capital/Financing Update (CAP)" since it relates to a financing transaction and valuation for acquisition purposes. However, the document is primarily a valuation report, which is not explicitly listed as a separate category. Given the nature of the document, the best fit is "Capital/Financing Update (CAP)" as it concerns valuation for a capital transaction (equity acquisition). Confidence is high due to the detailed valuation content and the context of acquisition.
2018-11-23 Chinese
董事会审计委员会关于全资子公司江河医疗签订股权转让协议暨关联交易的书面审核意见
Regulatory Filings Classification · 95% confidence The document is a written audit committee opinion regarding a related party transaction involving a subsidiary's equity transfer agreement. It discusses compliance with laws, fairness of the transaction, and the need for shareholder approval. The document is short (696 characters) and is a formal opinion or certification by the audit committee rather than a full audit report or financial statement. It does not contain financial data or detailed audit results but is an internal governance and compliance statement related to a specific transaction. Therefore, it fits best under Regulatory Filings (RNS) as it is a regulatory announcement or compliance document that does not qualify as a full Audit Report (AR) or Annual Report (10-K).
2018-11-23 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.